We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Decellurization Technique Enhances Study of ECM Structure

By LabMedica International staff writers
Posted on 12 Jul 2017
Print article
Image: The in situ decellularization of tissues (ISDoT) process reveals the ECM structure of a decellularized breast cancer lymphatic metastasis (Photo courtesy of Alejandro Mayorca-Guiliani).
Image: The in situ decellularization of tissues (ISDoT) process reveals the ECM structure of a decellularized breast cancer lymphatic metastasis (Photo courtesy of Alejandro Mayorca-Guiliani).
A new method has been developed that allows complete removal of cells from within organs of the body to enhance the study of extracellular membrane (ECM) composition and structure.

ECM is a master regulator of cellular phenotype and behavior. It has a crucial role in both normal tissue homeostasis and disease pathology. Differing mechanical properties in ECM exert effects on both cell behavior and gene expression. ECM can exist in varying degrees of stiffness and elasticity, from soft brain tissues to hard bone tissues. The elasticity of the ECM can differ by several orders of magnitude. This property is primarily dependent on collagen and elastin concentration, and it has recently been shown to play an influential role in regulating numerous cell functions.

Investigators at the University of Copenhagen (Denmark) reported in the June 12, 2017, online edition of the journal Nature Medicine that they had developed a fast and efficient approach to enhance the study of ECM composition and structure. Termed in situ decellularization of tissues (ISDoT), it allows whole organs to be decellularized, leaving native ECM architecture intact. These three-dimensional decellularized tissues can be studied using high-resolution fluorescence and second harmonic imaging, and can be used for quantitative proteomic interrogation of the ECM.

The investigators performed high-resolution sub-micron imaging of matrix topography in normal tissue and over the course of primary tumor development and progression to metastasis in mice. Results of these studies provided the first detailed imaging of the metastatic niche. Furthermore, these data showed that cancer-driven ECM remodeling was organ specific, and that it was accompanied by comprehensive changes in ECM composition and topological structure. The investigators also described differing patterns of basement-membrane organization surrounding different types of blood vessels in healthy and diseased tissues.

The investigators stated that their method was superior to other methods tested in its ability to preserve the structural integrity of the ECM, facilitate high-resolution imaging, and quantitatively detect ECM proteins.

"We have developed a technique to obtain intact organ scaffolds and to image them using microscopes. We are the first to image the structures of primary and metastatic tumors as well as healthy organs in this way," said senior author Dr. Janine Erler, professor in the biotech research and innovation center at the University of Copenhagen. "We are now re-introducing cells into our extracellular matrix scaffolds, bringing them back to life, to study how tumors form and how cancer progresses. This is extremely exciting and offers a unique opportunity to study how cells behave in their native environment."

Related Links:
University of Copenhagen

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis
New
TORCH Infections Test
TORCH Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.